Amyotrophic lateral sclerosis (ALS) presents challenges for diagnosis and objective monitoring of disease progression. We show, using pharmacologic MRI, that alterations in motor circuitry can be characterized using a passive stimulus in a rat model of familial ALS as a function of symptom progression. Presymptomatic familial ALS rats had a pattern of activation to amphetamine that was statistically indistinguishable from the wild-type controls. In contrast, symptomatic rats showed significantly decreased response in sensorimotor cortex and increased response in M2 motor cortex, caudate/putamen, and thalamus. These results are similar to findings in humans of altered response to motor tasks in ALS. It may be plausible to use a passive amphetamine challenge as a biomarker to assess progression of the disease and efficacy of potential treatments.
Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating disease with rapid degeneration of motor neurons in brain stem and spinal cord. Multiple pathways [1] are involved in motor neuron death in ALS including aberrant folding of superoxide dismutase and glutamate excitotoxicity [2] . Most cases are of unknown etiology. Therefore, diagnosing the disease can be a considerable challenge and it is difficult to exclude other motor neuron diseases such that final clinical diagnosis can often take several months [3] . Owing to the rapid progression of ALS (average life expectancy from diagnosis is 2-5 years), early diagnosis is imperative as it can allow for earlier treatment that may protect the motor neurons [4] .
Noninvasive neuroimaging tools may provide improved means for making early objective diagnoses, as well as aid in assessing etiologic mechanisms. Functional MRI (fMRI) is a tool that can map out patterns of motor circuitry and motor functions using the coupling of neuronal activity with associated changes in regional blood flow. A number of studies of ALS patients have examined the reorganization of motor circuitry as a consequence of the illness [5] [6] [7] . However, monitoring motor circuitry in ALS patients is difficult because of the inability of patients to perform even simple motor tasks at later stages. This necessitates coming up with a means of adjusting motor tasks for the ability of the participants to perform the studies. Furthermore, it can often preclude meaningful longitudinal comparisons as the motor abilities change more during disease progression. We therefore sought a means to assess motor circuitry using a passive challenge in a rat model of familial ALS (FALS). Earlier data in rats showed that amphetamine activates many components of the sensorimotor system, and further that it provides a sensitive measure of loss of motor function in Parkinson's disease models [8] [9] [10] . Furthermore, when challenged with amphetamine rats show a pronounced motor stimulus as measured by many different tests including locomotion and electrophysiology of striatal and motor neurons [11] . Amphetamine can also facilitate motor recovery after sensorimotor contusion [12] reflecting glutamatergic and dopaminergic interactions in the sensorimotor system [13] . Thus, we used pharmacologic MRI of a passive amphetamine challenge for longitudinal study of motor cortex/dopaminergic circuitry in FALS rats. Evidence in other diseases, such as multiple sclerosis or Alzheimer's disease, suggests MRI can provide a number of markers that can be used to shrink population sizes, decrease measurement times for following therapeutic interventions, and increase statistical power in clinical trials [14, 15] . Therefore, development of the passive pharmacologic challenge as a potential marker for motor neuron dysfunction in ALS may lead to a useful clinical tool.
Methods

Animals
Male Sprague-Dawley rats expressing SOD1 G93A [16] and wild-type (WT) littermates were purchased from Taconic (Hudson, New York, USA). All animals were scanned under 1-1.5% halothane anesthesia (mixed in N 2 O/O 2 ) wrapped with a circulating water blanket maintained at 381C. The tail vein was catheterized for contrast agent and amphetamine injection. We studied a total of seven animals. Three animals were followed longitudinally in the presymptomatic stage before any overt signs of motor impairment and then until development of partial hindlimb paralysis defined by the ability to use the forelimbs for locomotion while the hindlimbs were fully or partially paralyzed. To control for possible sensitization effects of amphetamine, an additional two presymptomatic animals and two postsymptomatic animals were studied, both of which were injected with amphetamine only once. The mean presymptomatic age was age 85 ± 28 days and postsymptomatic age was 131 ± 13 days. All procedures were approved by the Massachusetts General Hospital Subcommittee On Research Animal Care.
MRI
MRI experiments were carried out as described earlier at 9.4 T (Bruker, Billerica, Massachusetts, USA) using IRON (Increased Relaxivity for Optimized Neuroimaging) method to sensitize images to cerebral blood volume (CBV) changes [9, 17] . Four to five pre-MION (monocrystalline iron oxide nanoparticles) images were collected followed by MION injection (25 mg/kg, intravenously). Post-MION images were collected for at least 20 min and then amphetamine (2.5 mg/kg, intravenously; Sigma, St. Louis, Missouri, USA) was injected during continuous gradient echo imaging (TR/TE = 600/10 ms, FOV = 2.7 cm with 256 Â 128 in plane resolution, 0.75 mm slice Â 16 slices). For CBV, the transverse relaxation rate (R 2 *) was measured on a pixel by pixel basis using the standard formulation for gradient echo signal, R 2 *(t) = -ln[S (t) /S (0) ]/TE, where TE is the echo time and S (0) is the average value of the signal before MION. Data acquired after injection of MION were converted to percent change in functional CBV [fCBV (V) ] using the change in transverse relaxation rate relative to the precontrast baseline: fCBV = V (t) / V (0) = R (t) /R (0) -1. Then, the average CBV change over 30 min was calculated for each region of interest (ROI) for comparisons between brain regions and groups. For display purposes, maps of fCBV were made by fitting the fCBV time series to a g-function [19] and thresholded by correction for the number of pixels in the image.
Image coregistration and statistical comparisons
All images were registered onto the same standard brain template for subsequent averaging across animals as described earlier [18] . The data were resliced to a thickness of 0.5 mm. The template images are consistent with the stereotactic coordinate system atlas from Paxinos [19] . ROIs were drawn following those described in the Paxinos Atlas. Those analyzed are displayed in Fig. 1a .
Statistical analysis was performed using a one-way analysis of variance (ANOVA) for group differences (WT, presymptomatic, postsymptomatic) for each brain region, and then this was corrected for multiple comparisons using a Tukey's Honestly Significant Different correction post-hoc test. We further performed a repeated-measures ANOVA for the effects of symptom state on brain regional CBV changes in the three rats that were scanned longitudinally.
Results
A typical response to amphetamine produces a pattern that involves anterior somatosensory cortex (strongest in S1), cingulate, motor cortex (M1 and M2), caudate/ putamen (CPu), and thalamus. The ROIs used in this study, along with a representative map of amphetamine activation in a WT animal is shown in Fig. 1 . The presymptomatic animals had a response to amphetamine that was statistically indistinguishable from the WT animals ( Fig. 2a ). We performed a power analysis that showed that with the effect sizes and standard deviations observed in the presymptomatic and WT animals that we would need between 89 and 200 animals (depending upon brain region) to have 90% power to observe a difference between the WT and presymptomatic animals. In contrast, the symptomatic animals showed several significant changes in the maps including decreased response in sensorimotor cortex (S1 decreased by 40%) and large increases in M2 motor cortex ( + 90%), CPu ( + 70%), thalamus ( + 115%), and insula ( + 80%) ( Fig. 2b) . Time courses of the percentage fCBV changes from S1, M2, and CPu are shown in Fig. 3a . The shape of curves describing time course for S1 and CPu seem to be similar though their peak heights are changed between presymptomatic and symptomatic FALS animals ( Fig. 3a) . Interestingly, in M2 premotor cortex there was an increase in both the peak fCBV value and the fullwidth half-maximum of the fCBV time course from about 12-15 min in presymptomatic to about 35-45 min in the symptomatic FALS animals (Fig. 3b ).
To control for the possibility that we were simply observing amphetamine sensitization, we compared the three animals that were studied longitudinally to two additional symptomatic animals that had received just the single dose of amphetamine. The average fCBV in S1, M2, and CPu in the longitudinal (two doses) versus crosssectional (one dose) were 11.6 versus 10.6% (S1), 18.6 versus 15.3% (M2) and 23.6 versus 22.6% (CPu). All of these values are quite different from the presymptomatic values ( Fig. 3b ) and are not different from one another. Furthermore, repeated-measures ANOVA of just the three longitudinal animals yielded significance for CPu and M2, thalamus and insula.
Discussion
The rat model of FALS with overexpression of mutant human superoxide dismutase 1 shows a profound loss of Regions of interest and brain activation pattern after amphetamine administration. (a) Overlay of the brain regions analyzed on a standard rat atlas following Paxinos [19] . The data here are presented in 1-mm slice intervals. (b) Parametric map of statistically significant changes in functional cerebral blood volume (DfCBV) in a wild-type littermate control animal (significance defined as P < 0.05 corrected for the number of brain pixels). There is strong activation in sensorimotor cortex (S1) and caudate/putamen. motor function that is rapidly progressive. The pathology starts with vacuolation and loss of lower motor neurons and eventually progresses from loss of hindlimb function to all four limbs [20] . Loss of motor function can lead to cortical reorganization. Imaging techniques such as fMRI have provided insights into cortical reorganization caused after neuronal loss, such as in stroke [21] . There have been a number of fMRI studies of motor function in ALS patients [6, 7, 22] . These studies showed a pattern of recruitment of additional cortical (premotor) and anterior motor areas, while performing a motor task concomitant with loss of motor cortex activation [6] and/or somatosensory and sensorimotor cortex [7] . Amphetamine stimulation produces intense locomotor activity when administered to awake rats [11] and, in the magnet, produces a pattern of brain activation that includes many components of the motor system including motor cortex, sensory cortex, and basal ganglia [8, 9] . The alterations in the patterns of motor system activation observed in the ALS patients are similar to the alterations we find in the rat model of ALS with amphetamine stimulation after symptoms progress. We found in rats that there is a decrease in somatosensory cortex (S1) with an increase in anterior (especially M2) motor cortex. Furthermore, the large increase we note in the CPu as the animals become symptomatic is consistent with the results of Tessitore et al. [7] in humans, where they noted increased putaminal activity with a motor task. Unfortunately, rapid degeneration of motor neurons in ALS patients renders the evaluation of motor tasks progressively more difficult with time and the same task is more difficult for patients than controls, and thus making it harder to differentiate results originating from the pathology of neurodegeneration or from the changing Quantitative changes in time courses and functional cerebral blood volume (fCBV) values. (a) Averaged temporal pattern of CBV changes in three selected ROIs including S1 (sensorimotor cortex; decreased CBV), M2 (thalamus; increased CBV and FWHM of the time course) and caudate/ putamen (Cpu) (increased CBV). There were five animals per group. (b) Regional changes in CBV across groups including wild-type (WT; n = 6), pre-symptomatic (n = 5), and symptomatic (n = 5). *P < 0.05; **P < 0.01, by analysis of variance (see text).
difficulty of the task. Thus, the amphetamine provides an alternative means to stimulate the motor system passively.
Two other studies examined passive conditions in ALS patients. A PET study showed that CBF at rest in the primary sensorimotor cortex was significantly lower in ALS patients than in controls [5] . Another study using cutaneous stimulation, as a form of passive stimuli, of the hand and sole to elicit the palmomental response and plantar response in ALS patients showed that patients activated a significantly smaller volume of the contralateral sensorimotor cortex compared with controls [22] . These studies, along with ours, implicate the loss of neurons in sensorimotor cortex in ALS patients.
Besides from loss of sensorimotor cortex activity and increased premotor cortex (M2) activity, we also found a large increase of response in the Cpu in the symptomatic animals. This finding can potentially be explained in the following manner. There is glutamate input from sensory and motor cortex to striatum and glutamate decreases striatal dopamine (DA) D 2 receptor (D 2 R) synthesis in animal studies [23] . Motor cortex densely innervates dorsolateral striatum and amphetamine typically activates brain regions where DA receptors are richly expressed including motor cortex and striatum. There is decreased striatal D 2 R binding in vivo in drug-naive sporadic ALS patients [24] . Decreased D 2 R tone may lead to increased DA release after amphetamine. In an earlier study using microdialysis and pharmacologic MRI, we showed that D 2 antagonism increases DA release and fCBV [25] . We have also found that increased DA release, as measured using microdialysis, leads to increased CBV in the CPu [8, 9, 25] . Thus, a potentiation of DA release as a result of decreased D 2 tone may explain the large increase in activation that we find in striatum from symptomatic FALS rats.
As amphetamine is commonly prescribed for ADHD, and has been used as an adjunct to physical therapy in stroke in humans [26] or cortical injury in rats [12] , it may represent an alternative passive stimulus to electrical stimulation of extremities in ALS. Further studies examining relationship between pathological changes in both motor neurons and spinal cord and the altered patterns of brain activity will allow for determination of the added value of this tool compared with existing clinical markers.
Conclusion
MRI of a passive motor stimulus elicited by the drug amphetamine produces a pronounced alteration in the pattern of brain activity as a function of the symptomatic state of the FALS rats. The changes noted in the symptomatic stages of the disease are paralleled by similar changes observed using motor tasks using either PETor fMRI in ALS patients, which include upregulation of premotor areas and loss of activity in primary motor and sensory cortex.
